CIGB 300

Drug Profile

CIGB 300

Alternative Names: CIGB-300; IGBC-300; P15-Tat

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Elea; Heber Biotec
  • Class Antineoplastics; Apoptosis regulatory proteins; Peptides
  • Mechanism of Action Apoptosis stimulants; Casein kinase II inhibitors; Nucleophosmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II/III Condylomata acuminata
  • Phase II Cervical cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 01 Jan 2016 Elea completes phase II clinical trials in Cervical cancer in Argentina (Intralesional)
  • 23 Jun 2015 CIGB 300 is still in phase II trials for Cervical cancer in Argentina
  • 23 Jun 2015 Clinical development for Condylomata acuminata is ongoing in Argentina
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top